Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,843 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma of the Prostate Clear all
Recruiting No phase listed Observational

Active Surveillance for Cancer of the Prostate (ASCaP)

NCT00949819
View directory record Official record
Conditions
Prostate Cancer
Interventions
Active surveillance
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 30, 2026, 7:22 PM EDT
Completed No phase listed Observational

Men Undergoing Radical Prostatectomy

NCT00582530
View directory record Official record
Conditions
Prostate Cancer
Interventions
Whole Blood Draw
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Sep 30, 2026, 7:22 PM EDT
Recruiting Phase 1 Interventional

IDOV-Immune for Advanced Solid Tumors

NCT06910657
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 30, 2026, 7:22 PM EDT
Active, not recruiting Phase 2 Interventional

Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy

NCT05842057
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy
Interventions
BioDFence G3 Placental Tissue Membrane, Robot-Assisted Radical Prostatectomy
Biological · Procedure
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 30, 2026, 7:22 PM EDT
Not listed Phase 2 Interventional

A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer

NCT00218205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Epirubicin, Estramustine Phosphate, Celecoxib
Drug
Lead sponsor
Department of Veterans Affairs, New Jersey
Federal
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Sep 30, 2026, 7:22 PM EDT
Not yet recruiting Phase 2 Interventional

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

NCT07568756
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Cancer
Interventions
Flotufolastat F18 PET
Diagnostic Test
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 30, 2026, 7:22 PM EDT
Terminated Phase 1 Interventional Results available

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

NCT02995330
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bone marrow transplantation, Cytoxan, testosterone cypionate
Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Sep 30, 2026, 7:22 PM EDT
Active, not recruiting Phase 2 Interventional

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

NCT06463457
View directory record Official record
Conditions
Prostate Cancer, Advanced Prostate Cancer, Hormone Sensitive Prostate Cancer
Interventions
Darolutamide, Relugolix
Drug
Lead sponsor
Atish Choudhury, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 30, 2026, 7:22 PM EDT
Terminated Phase 1 Interventional

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

NCT04586335
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer
Interventions
CYH33
Drug
Lead sponsor
Haihe Biopharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
New Haven, Connecticut • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 30, 2026, 7:22 PM EDT
Recruiting Phase 2 Interventional

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

NCT06150417
View directory record Official record
Conditions
Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
Interventions
Androgen deprivation therapy (ADT), Androgen receptor signaling inhibitor (ARSI), Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT), Metastasis directed radiotherapy (MDRT)
Drug · Other · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 30, 2026, 7:22 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

NCT02893917
View directory record Official record
Conditions
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma With Neuroendocrine Differentiation, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Cediranib, Olaparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
16
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 1 Interventional

Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody

NCT00538668
View directory record Official record
Conditions
Prostate Cancer
Interventions
117Lu-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 85 Years · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer

NCT00642018
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, LY2181308 sodium, Prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 30, 2026, 7:22 PM EDT
Withdrawn No phase listed Observational

A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy

NCT01279785
View directory record Official record
Conditions
Prostate Cancer
Interventions
123I-MIP-1072
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Addressing Prostate Cancer Information Disparities With eHealth Technology

NCT02787434
View directory record Official record
Conditions
Prostate Neoplasm
Interventions
Prostate Cancer Screening Decision Aid
Other
Lead sponsor
Tufts University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Medford, Massachusetts • Atlanta, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 30, 2026, 7:22 PM EDT
Completed No phase listed Observational

Comparing Pre-Anesthesia Evaluation Via Telemedicine Versus in Person for Surgical Patients at Moffitt Cancer Center

NCT05065944
View directory record Official record
Conditions
Gynecologic Cancer, Prostate Cancer, Patient Satisfaction
Interventions
Telemedicine, In Person Visit
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer

NCT00345293
View directory record Official record
Conditions
Prostate Cancer
Interventions
autologous dendritic cell vaccine (DC/PC3)
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 30, 2026, 7:22 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NCT05053152
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy
Procedure · Other · Drug + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
242
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Not applicable Interventional

Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors

NCT02150148
View directory record Official record
Conditions
Cancer
Interventions
Experimental: Mentored Gardening Intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Phase 2 Interventional

Study of Oxaliplatin and Taxotere in Prostate Cancer

NCT00260611
View directory record Official record
Conditions
Prostate Cancer
Interventions
Oxaliplatin, Taxotere
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Not applicable Interventional Results available

Urology San Antonio MRI/MicroUS Comparison

NCT03762616
View directory record Official record
Conditions
Prostate Cancer
Interventions
Micro-ultrasound targeted biopsy, mpMRI targeted biopsy
Diagnostic Test
Lead sponsor
Exact Imaging
Industry
Eligibility
40 Years to 75 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 30, 2026, 7:22 PM EDT
Completed Not applicable Interventional

Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery

NCT02144649
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
dietary intervention (tangerine tomato juice), dietary intervention (red tomato juice), questionnaire administration, Correlative studies
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Columbus, Ohio • Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Sep 30, 2026, 7:22 PM EDT
Terminated Not applicable Interventional Results available

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel

NCT02491411
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer
Interventions
Dexamethasone, Enzalutamide, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 30, 2026, 7:22 PM EDT
Recruiting Early Phase 1 Interventional

HCQ in Resectable Localized Prostate Cancer

NCT06408298
View directory record Official record
Conditions
Resectable Localized Prostate Cancer
Interventions
Hydroxychloroquine Sulfate 400Mg Tab, Placebo
Drug
Lead sponsor
Lionel.D.Lewis, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 30, 2026, 7:22 PM EDT